Physician profile
Charles E Lerner
NPI 1548440860
$2,659.89
in general payments reported to CMS, 2019-2025
17 companies · $15.13 in 2025
The $15.13 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $351 · 2021: $394 · 2022: $376 · 2023: $397 · 2024: $243 · 2025: $15.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $977.81 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $670.43 | 2019-2025 | |
| Pentax of America, INC. | $168.51 | 2021 | |
| Nevro Corp. | $127.40 | 2023 | Senza |
| Allergan, INC. | $123.21 | 2019 | |
| Glaxosmithkline, LLC. | $105.32 | 2020 | |
| Amgen INC. | $99.82 | 2021 | |
| Amarin Pharma, INC. | $90.01 | 2020 | |
| Melinta Therapeutics, LLC | $71.63 | 2023 | Kimyrsa |
| Abbott Laboratories | $71.45 | 2023 | Eterna |
| Novo Nordisk INC | $54.00 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $21.25 | 2019 | |
| Corcept Therapeutics | $20.74 | 2024 | Korlym |
| Lilly USA, LLC | $17.52 | 2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.19 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.02 | 2020 | |
| Merck Sharp & Dohme LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.